Keyword: Merck

The deal will give Merck control of an experimental oral HIF-2α inhibitor that may challenge Keytruda for the metastatic renal cell carcinoma market.

British biotech is often a disregarded backwater in life sciences, but today a host of good news has shone the spotlight back onto its potential.

An Astra-Zeneca led research team has discovered a weakness in the process by which cancer cells to become resistant to MEK inhibition.

Kymab has hired on a new CEO, Simon Sturge, to usher the antibody specialist into its next phase of growth.

Injecting a vaccine into tumor sites produced remissions in mice and some lymphoma patients in a study at Mount Sinai.

Soon-Shiong sued over "catch-and-kill" of Abraxane rival; Gottlieb reflects on tenure as FDA chief; and British biotech Artios nabs Lilly, AZ veteran.

The BRACAnalysis CDx test will be used to hunt for germline BRCA mutations in men eligible for the Big Pharmas’ PARP-inhibiting Lynparza therapy.

Fatty liver disease biotech NGM Bio has got off a $107 million IPO, following in the footsteps of rival GenFit.

At the annual meeting of the American College of Cardiology this week, a new analysis of Merck’s anacetrapib cast a shadow on DalCor’s hypothesis

Merck is extending its 2015 R&D pact with NGM Bio for a broad range of early-stage assets. It's also culling one therapy that didn't work out.